Phase 2a Study of Danicamtiv (MYK-491) in Patients with ChronicHeart Failure with Reduced

Ejection Fraction (HFrEF)

Adriaan A Voors

University of Groningen, Groningen, Netherlands

Presenting author received consultancy fees and/or research support from Amgen, AstraZeneca, Bayer AG, Boehringer Ingelheim, Cytokinetics, Merck,

Myokardia, NovoNordisk, Novartis, Roche Diagnostics

This study was funded by MyoKardia, Inc.

Danicamtiv (formerly MYK-491) is an investigational drug

2

HFrEF, heart failure with reduced ejection fraction; LA, left atrial; LV, left ventricular.

Introduction

1. Fernandes S, et al. In: AHA Scientific Sessions. 2019: Abstract 140, p. A15707. Circulation; 2. Tamby J-F, et al. In: ESC Heart Failure Scientific Sessions. 2019: Abstract P1702. HFrEF, heart failure with reduced ejection fraction

AF, atrial fibrillation; BID, twice daily; d, day; eGFR, estimated glomerular filtration rate; HFrEF, heart failure with reduced ejection fraction; ULN, upper limit normal.

Attachments

  • Original document
  • Permalink

Disclaimer

MyoKardia Inc. published this content on 22 June 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 June 2020 12:06:02 UTC